Lercanidipine (BioDeep_00000018236)

human metabolite blood metabolite Chemicals and Drugs

代谢物信息卡片

3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

化学式: C36H41N3O6 (611.2995206)
中文名称: 乐卡地平
谱图信息: 最多检出来源 Homo sapiens(blood) 4.6%

分子结构信息

SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
InChI: InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3

描述信息

Lercanidipine is only found in individuals that have used or taken this drug. It is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

9 个代谢物同义名

3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Biohorm brand OF lercanidipine hydrochloride; Lercanidipine hydrochloride; Lercanidipine; Lercadip; Lercanil; Zanidip; Lerdip

数据库引用编号

10 个数据库交叉引用编号

ChEBI: CHEBI:135930
KEGG: C13971
PubChem: 65866
HMDB: HMDB0014669
DrugBank: DB00528
ChEMBL: CHEMBL250270
Wikipedia: Lercanidipine
chemspider: 59276
CAS: 100427-26-7
PMhub: MS000004471

分类词条

Quinazolines

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Amal A El-Masry, Dalia R El-Wasseef, Manal Eid, Ihsan A Shehata, Abdallah M Zeid. Optimization and Validation of a Facile RP-HPLC Method for Determination of Betrixaban and Lercanidipine in Pharmaceutical and Biological Matrices. Journal of chromatographic science. 2021 Aug; 59(8):785-794. doi: 10.1093/chromsci/bmab088. [PMID: 34215884]
Mohammad Hassan Baig, Tanuj Sharma, Irfan Ahmad, Mohammed Abohashrh, Mohammad Mahtab Alam, Jae-June Dong. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules (Basel, Switzerland). 2021 Mar; 26(6):. doi: 10.3390/molecules26061678. [PMID: 33802860]
Mohammad M Ghahremanpour, Julian Tirado-Rives, Maya Deshmukh, Joseph A Ippolito, Chun-Hui Zhang, Israel Cabeza de Vaca, Maria-Elena Liosi, Karen S Anderson, William L Jorgensen. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS medicinal chemistry letters. 2020 Dec; 11(12):2526-2533. doi: 10.1021/acsmedchemlett.0c00521. [PMID: 33324471]
Estela Hanauer Schaab, Vera Lucia Lanchote, Glauco Henrique Balthazar Nardotto, Maria Paula Marques Pereira, Márcio Dantas, Carlos Eduardo Paiva, Eduardo Barbosa Coelho. Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. Journal of clinical pharmacology. 2020 01; 60(1):75-85. doi: 10.1002/jcph.1485. [PMID: 31353479]
A I Khotko, D N Khotko, N B Zakharova, A I Tarasenko, V M Popkov, A V Alekseev. [Nephroprotective effect of calcium channel blocker lercanidipine in treatment of patients with urolithiasis and urinary tract obstruction and monitoring of the serum cytokine profile]. Urologiia (Moscow, Russia : 1999). 2019 Dec; ?(5):48-52. doi: 10.18565/urology.2019.5.48-52. [PMID: 31808632]
Giuseppe Mancia, Kostantinos Tsioufis. Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine. Future cardiology. 2019 07; 15(4):259-266. doi: 10.2217/fca-2019-0008. [PMID: 31180724]
K Tsioufis, Costas Tsioufis, Kyriakos Dimitriadis, Emmanouil Mantzouranis, Ilianna Mani, Dimitrios Tousoulis. Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Current medical research and opinion. 2016 10; 32(sup2):35-41. doi: 10.1080/03007995.2016.1218839. [PMID: 27779461]
Nicolas Roberto Robles, Carlos Calvo, Javier Sobrino, Eugenia Espinel, Rafael Esteban, Lourdes Mateos, Juan F Macias. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Current medical research and opinion. 2016 10; 32(sup2):29-34. doi: 10.1080/03007995.2016.1218838. [PMID: 27779460]
Xiaobing Li, Fuguo Shi, Xiaojing He, Lingyan Jian, Li Ding. A rapid and sensitive LC-MS/MS method for determination of lercanidipine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. Journal of pharmaceutical and biomedical analysis. 2016 Sep; 128(?):67-72. doi: 10.1016/j.jpba.2016.05.013. [PMID: 27232153]
M V Melnik, I I Afonicheva, A V Beloborodova. [THE ROLE PLEIOTROPIC EFFECTS OF CALCIUM CHANNEL BLOCKER LERCANIDIPINE IN PERIOPERATIVE THERAPY OF ARTERIAL HYPERTENSION.]. Anesteziologiia i reanimatologiia. 2016 Sep; 61(5):395-398. doi: . [PMID: 29489111]
Giuseppe Derosa, Amedeo Mugellini, Rosa Maria Pesce, Angela D'Angelo, Pamela Maffioli. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC cardiovascular disorders. 2016 Apr; 16(?):66. doi: 10.1186/s12872-016-0237-z. [PMID: 27068332]
Gino Seravalle, Gianmaria Brambilla, Daniela Prata Pizzalla, Anna Casati, Marta Riva, Cesare Cuspidi, Michele Bombelli, Giuseppe Mancia, Guido Grassi. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. Journal of the American Society of Hypertension : JASH. 2016 Mar; 10(3):244-51. doi: 10.1016/j.jash.2016.01.006. [PMID: 26831124]
Giuseppe Derosa, Amedeo Mugellini, Fabrizio Querci, Ivano Franzetti, Rosa Maria Pesce, Angela D'Angelo, Pamela Maffioli. Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. Scientific reports. 2015 Aug; 5(?):12603. doi: 10.1038/srep12603. [PMID: 26243165]
E V Gosteva, L V Vasil'eva. [Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Proffie in Elderly Patients With Arterial Hypertension]. Kardiologiia. 2015; 55(2):32-6. doi: . [PMID: 26164986]
Daniel Duda-Seiman, Corina Duda-Seiman, Florin Borcan, Livia-Cristina Borcan, Silvia Mancas, Speranta Avram. Calcium Channel Blockers--Benefits Upon Vascular Biology in Hypertensive Patients. Cardiovascular & hematological agents in medicinal chemistry. 2015; 13(1):54-62. doi: 10.2174/187152571301150730115442. [PMID: 26245661]
Meng Peng, Xiong-jing Jiang, Hui Dong, Yu-bao Zou, Hui-min Zhang, Hai-ying Wu, Yuejin Yang. Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?. Current medical research and opinion. 2015 Jan; 31(1):177-82. doi: 10.1185/03007995.2014.960071. [PMID: 25424908]
Prashant Nasa, Akhilesh Singh, Deven Juneja, Omender Singh, Yash Javeri. Continuous venovenous hemodiafiltration along with charcoal hemoperfusion for the management of life-threatening lercanidipine and amlodipine overdose. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2014 Nov; 25(6):1255-8. doi: 10.4103/1319-2442.144262. [PMID: 25394445]
G Derosa, A Bonaventura, D Romano, L Bianchi, E Fogari, A D'Angelo, P Maffioli. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. Journal of clinical pharmacy and therapeutics. 2014 Jun; 39(3):277-85. doi: 10.1111/jcpt.12139. [PMID: 24635387]
Giuseppe Derosa, Aldo Bonaventura, Davide Romano, Lucio Bianchi, Elena Fogari, Angela D'Angelo, Pamela Maffioli. Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. Journal of the American Society of Hypertension : JASH. 2014 Jun; 8(6):422-8. doi: 10.1016/j.jash.2014.03.329. [PMID: 24836352]
Nisharani S Ranpise, Swati S Korabu, Vinod N Ghodake. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids and surfaces. B, Biointerfaces. 2014 Apr; 116(?):81-7. doi: 10.1016/j.colsurfb.2013.12.012. [PMID: 24445002]
Carolina De Ciuceis, Massimo Salvetti, Claudia Rossini, Maria Lorenza Muiesan, Anna Paini, Sarah Duse, Elisa La Boria, Francesco Semeraro, Anna Cancarini, Claudia Agabiti Rosei, Annamaria Sarkar, Giuseppina Ruggeri, Luigi Caimi, Doris Ricotta, Damiano Rizzoni, Enrico Agabiti Rosei. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. Journal of hypertension. 2014 Mar; 32(3):565-74. doi: 10.1097/hjh.0000000000000067. [PMID: 24378999]
Michel Burnier. Renal protection with calcium antagonists: the role of lercanidipine. Current medical research and opinion. 2013 Dec; 29(12):1727-35. doi: 10.1185/03007995.2013.842891. [PMID: 24069902]
R Farah, R Khamisy-Farah, R Shurtz-Swirski. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. International angiology : a journal of the International Union of Angiology. 2013 Feb; 32(1):85-93. doi: NULL. [PMID: 23435396]
L O Minushkina. [Treatment of arteril hypertension in patients with chronic kidney disease: a fixed combination of lercanidipine and enalapril]. Kardiologiia. 2013; 53(12):64-9. doi: . [PMID: 24800484]
Keguang Chen, Jing Zhang, Sha Liu, Dujuan Zhang, Yanni Teng, Chunmin Wei, Benjie Wang, Xiaoyan Liu, Guiyan Yuan, Rui Zhang, Wenjing Zhao, Ruichen Guo. Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Jun; 899(?):1-7. doi: 10.1016/j.jchromb.2012.04.014. [PMID: 22622066]
Arrigo F G Cicero, Beatrice Gerocarni, Martina Rosticci, Claudio Borghi. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clinical and experimental hypertension (New York, N.Y. : 1993). 2012; 34(2):113-7. doi: 10.3109/10641963.2011.601381. [PMID: 21967031]
Colin Gerard Egan, Roberto Pontremoli. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. Journal of nephrology. 2011 Jul; 24(4):428-37. doi: 10.5301/jn.2011.6271. [PMID: 21279953]
NULL. [Fixed combination enalapril/lercanidipine in routine treatment: consistent RR reduction with kidney protection]. MMW Fortschritte der Medizin. 2011 Jan; 153(3):42-3. doi: NULL. [PMID: 22165604]
P-J Hsiao, H-W Lin, C-C Sung, C-W Wang, P Chu, S-H Lin. Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis. Clinical nephrology. 2010 Sep; 74(3):217-22. doi: 10.5414/cnp74217. [PMID: 20860906]
Gregorio Milani, Monica Ragazzi, Giacomo D Simonetti, Gian P Ramelli, Mattia Rizzi, Mario G Bianchetti, Emilio F Fossali. Superior palatability of crushed lercanidipine compared with amlodipine among children. British journal of clinical pharmacology. 2010 Feb; 69(2):204-6. doi: 10.1111/j.1365-2125.2009.03580.x. [PMID: 20233185]
Claudio Borghi, Arrigo F G Cicero. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clinical drug investigation. 2010; 30(12):843-54. doi: 10.1007/bf03256912. [PMID: 20923243]
N R Robles, B Romero, E Garcia de Vinuesa, E Sánchez-Casado, J J Cubero. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Renal failure. 2010 Jan; 32(2):192-7. doi: 10.3109/08860220903541135. [PMID: 20199181]
Sachin S Pandit, Arun T Patil. Formulation and in vitro evaluation of buoyant controlled release lercanidipine lipospheres. Journal of microencapsulation. 2009 Nov; 26(7):635-41. doi: 10.3109/02652040802593908. [PMID: 19839799]
Yu-Tzu Tsao, Wei-Liang Chen. Calcium channel blocker-induced chylous ascites in peritoneal dialysis. Kidney international. 2009 Apr; 75(8):868. doi: 10.1038/ki.2008.334. [PMID: 19337227]
Vanessa Bergamin Boralli, Eduardo Barbosa Coelho, Stefânia Amaral Sampaio, Maria Paula Marques, Vera Lucia Lanchote. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. Journal of clinical pharmacology. 2009 Feb; 49(2):205-11. doi: 10.1177/0091270008327536. [PMID: 19033449]
Jiunn-Ren Wu, Shu-Fen Liou, Shin-Wha Lin, Chee-Yin Chai, Zen-Kong Dai, Jyh-Chong Liang, Ing-Jun Chen, Jwu-Lai Yeh. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacological research. 2009 Jan; 59(1):48-56. doi: 10.1016/j.phrs.2008.09.015. [PMID: 18973813]
Cevat Topal, Reha Erkoc, Hayriye Sayarlioglu, Ekrem Dogan, Huseyin Beyenik. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. Renal failure. 2009; 31(6):446-51. doi: 10.1080/08860220902979364. [PMID: 20187715]
Marcio L L Martinez, Elen Rizzi, Michele M Castro, Karla Fernandes, Lusiane M Bendhack, Raquel F Gerlach, Jose E Tanus-Santos. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. European journal of pharmacology. 2008 Dec; 599(1-3):110-6. doi: 10.1016/j.ejphar.2008.10.007. [PMID: 18930722]
Wei-Shun Yang, Jenq-Wen Huang, Huei-Wen Chen, Tun-Jun Tsai, Kwan-Dun Wu. Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2008 Nov; 28(6):632-6. doi: 10.1177/089686080802800615. [PMID: 18981394]
R Farah, R Shurtz-Swirski. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients. Minerva cardioangiologica. 2008 Oct; 56(5):467-76. doi: NULL. [PMID: 18813182]
Marcio L L Martinez, Michele M Castro, Elen Rizzi, Karla Fernandes, Caroline Demacq, Lusiane M Bendhack, Raquel F Gerlach, Jose E Tanus-Santos. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. European journal of pharmacology. 2008 Sep; 591(1-3):224-30. doi: 10.1016/j.ejphar.2008.06.096. [PMID: 18634778]
Talma Rosenthal, Eliezer Rosenmann, Daniele Tomassoni, Francesco Amenta. Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats. Journal of cardiovascular pharmacology and therapeutics. 2007 Jun; 12(2):145-52. doi: 10.1177/1074248407300621. [PMID: 17562785]
Revital Shurtz-Swirski, Raymond Farah, Shifra Sela, Galina Shapiro, Regina Klempef, Tamara Snitkovski, Batya Kristal. [The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients]. Harefuah. 2006 Dec; 145(12):895-9, 942. doi: NULL. [PMID: 17220028]
Jan Menne, Joon-Keun Park, Rahul Agrawal, Carsten Lindschau, Jan T Kielstein, Torsten Kirsch, Axel Marx, Dominik Muller, Ferdinand H Bahlmann, Matthias Meier, Stefanie M Bode-Böger, Hermann Haller, Danilo Fliser. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2006 May; 20(7):994-6. doi: 10.1096/fj.05-4087fje. [PMID: 16597674]
Marcio L L Martinez, Lívia F Lopes, Eduardo B Coelho, Fernando Nobre, João B T Rocha, Raquel F Gerlach, Jose E Tanus-Santos. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. Journal of cardiovascular pharmacology. 2006 Jan; 47(1):117-22. doi: 10.1097/01.fjc.0000196241.96759.71. [PMID: 16424795]
Madgalene Kalovidouris, Stavroula Michalea, Nikoleta Robola, Maria Koutsopoulou, Irene Panderi. Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma. Rapid communications in mass spectrometry : RCM. 2006; 20(19):2939-46. doi: 10.1002/rcm.2693. [PMID: 16941725]
Bernard M Y Cheung, Yu Bun Manil, Hung Fat Tse, Cyrus R Kumana, Chu-Pak Lau. Advantages of blood pressure optimization. Advances in therapy. 2005 Jul; 22(4):285-96. doi: 10.1007/bf02850078. [PMID: 16418138]
N R Robles, J Ocon, C F Gomez, M Manjon, L Pastor, J Herrera, J Villatoro, J Calls, J Torrijos, V I Rodríguez, M M A Rodriguez, M L Mendez, A Morey, F I Martinez, J Marco, A Liebana, B Rincon, F Tornero. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Renal failure. 2005; 27(1):73-80. doi: NULL. [PMID: 15717638]
Valquiria Aparecida Polisel Jabor, Eduardo Barbosa Coelho, Vera Lucia Lanchote. Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Dec; 813(1-2):343-6. doi: 10.1016/j.jchromb.2004.09.038. [PMID: 15556551]
Monica Canavesi, Novella Baldini, Amedeo Leonardi, Giorgio Sironi, Stefano Bellosta, Franco Bernini. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. Journal of cardiovascular pharmacology. 2004 Oct; 44(4):416-22. doi: 10.1097/01.fjc.0000139448.56713.3d. [PMID: 15454849]
Isam Ismail Salem, Jafer Idrees, Jaafar I Al Tamimi, Pierluigi Farina. Selective and rapid liquid chromatography-mass spectrometry method for the determination of lercanidipine in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Apr; 803(2):201-7. doi: 10.1016/j.jchromb.2003.12.019. [PMID: 15063326]
N R Robles, L Pastor, M Manjón, J Ocón, F Gómez Campderá, J Herrera, J Villatoro, J Calls, J Torrijos, I Rodríguez Villareal, M A Rodríguez Martínez, M L Méndez, A Morey, J Martínez Fernández, J Marco, A Liébana, B Rincón, F Tornero. [Lercanidipine in diabetic patients with renal failure]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2004; 24(4):338-43. doi: NULL. [PMID: 15455493]
Valquiria Aparecida Polisel Jabor, Eduardo Barbosa Coelho, Demian Rocha Ifa, Pierina Sueli Bonato, Neife Aparecida Guinaim dos Santos, Vera Lucia Lanchote. Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Nov; 796(2):429-37. doi: 10.1016/j.jchromb.2003.08.029. [PMID: 14581082]
Andrea Mosca, Renata Paleari, Ferruccio Ceriotti, Annunziata Lapolla, Domenico Fedele. Biological variability of albumin excretion rate and albumin-to-creatinine ratio in hypertensive type 2 diabetic patients. Clinical chemistry and laboratory medicine. 2003 Sep; 41(9):1229-33. doi: 10.1515/cclm.2003.188. [PMID: 14598874]
Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Luca Corradi, Andrea Rinaldi, Giuseppe Derosa, Paola Preti. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. American journal of hypertension. 2003 Jul; 16(7):596-9. doi: 10.1016/s0895-7061(03)00901-4. [PMID: 12850395]
Stefano Taddei, Agostino Virdis, Lorenzo Ghiadoni, Daniele Versari, Guido Salvetti, Armando Magagna, Antonio Salvetti. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (Dallas, Tex. : 1979). 2003 Apr; 41(4):950-5. doi: 10.1161/01.hyp.0000063361.70525.3c. [PMID: 12642509]
Guido Grassi, Gino Seravalle, Carlo Turri, GianBattista Bolla, Giuseppe Mancia. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension (Dallas, Tex. : 1979). 2003 Mar; 41(3):558-62. doi: 10.1161/01.hyp.0000058003.27729.5a. [PMID: 12623959]
Julie Massicotte, Antoine Viens, Ming-Hui Yao, Amedeo Leonardi, Giorgio Sironi, Hongbo Wang, Louis Dumont. Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters. Acta pharmacologica Sinica. 2003 Mar; 24(3):199-206. doi: NULL. [PMID: 12617766]
Domenico Acanfora, Luigi Trojano, Mihai Gheorghiade, Costantino Picone, Antimo Papa, Giuseppe Furgi, Franca Giuliano, Roberto Maestri, Franco Rengo. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. American journal of therapeutics. 2002 Sep; 9(5):444-53. doi: 10.1097/00045391-200209000-00013. [PMID: 12237738]
Rita Rachmani, Zohar Levi, Bat-Sheva Zadok, Mordchai Ravid. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clinical pharmacology and therapeutics. 2002 Sep; 72(3):302-7. doi: 10.1067/mcp.2002.127110. [PMID: 12235451]
Giorgio L Viviani. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. Journal of cardiovascular pharmacology. 2002 Jul; 40(1):133-9. doi: 10.1097/00005344-200207000-00016. [PMID: 12072586]
C Venkata S Ram. Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension. The American journal of cardiology. 2002 Jan; 89(2):214-5. doi: 10.1016/s0002-9149(01)02203-2. [PMID: 11792345]
Ulrich Klotz. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittel-Forschung. 2002; 52(3):155-61. doi: 10.1055/s-0031-1299873. [PMID: 11963641]
Maurizio Sabbatini, Amedeo Leonardi, Rodolfo Testa, Daniele Tomassoni, Lucia Vitaioli, Francesco Amenta. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. Journal of cardiovascular pharmacology. 2002 Jan; 39(1):39-48. doi: 10.1097/00005344-200201000-00005. [PMID: 11743226]
L Incandela, G Belcaro, M R Cesarone, M T De Sanctis, M Griffin, M Cacchio, A N Nicolaides, M Bucci, A Barsotti, G Martines, U Cornelli, A Di Renzo. Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. International angiology : a journal of the International Union of Angiology. 2001 Jun; 20(2):136-40. doi: NULL. [PMID: 11533521]
M Sabbatini, L Vitaioli, E Baldoni, F Amenta. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. The Journal of pharmacology and experimental therapeutics. 2000 Sep; 294(3):948-54. doi: NULL. [PMID: 10945845]
S Bellosta, F Bernini. Lipophilic calcium antagonists in antiatherosclerotic therapy. Current atherosclerosis reports. 2000 Jan; 2(1):76-81. doi: 10.1007/s11883-000-0098-9. [PMID: 11122728]
J M Krzesinski. [Pharma-clinics. Drug of the month. Lercanidipine (Zanidip)]. Revue medicale de Liege. 1999 Oct; 54(10):832-4. doi: NULL. [PMID: 10605321]
L G Herbette, M Vecchiarelli, A Sartani, A Leonardi. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood pressure. Supplement. 1998; 2(?):10-7. doi: NULL. [PMID: 9850437]
A Corsini, M R Accomazzo, M Canavesi, A Sartani, R Testa, A L Catapano, R Fumagalli, R Paoletti, F Bernini. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved?. Blood pressure. Supplement. 1998; 2(?):18-22. doi: 10.1080/080370598438997. [PMID: 9850438]
P A van Zwieten. The pharmacological properties of lipophilic calcium antagonists. Blood pressure. Supplement. 1998; 2(?):5-9. doi: ". [PMID: 9850436]
A Corsini, M Bonfatti, P Quarato, M R Accomazzo, M Raiteri, A Sartani, R Testa, S Nicosia, R Paoletti, R Fumagalli. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. Journal of cardiovascular pharmacology. 1996 Nov; 28(5):687-94. doi: 10.1097/00005344-199611000-00012. [PMID: 8945683]